Mon Dec 08 13:00:00 UTC 2025: Okay, here’s a news article based on the provided text:

Wave Life Sciences Stock Soars on Promising Obesity Drug Results

CAMBRIDGE, MA – Shares of Wave Life Sciences (WVE) surged nearly 45% in premarket trading today, reaching $10.85, after the company announced positive early-stage clinical trial results for its experimental obesity drug, WVE-007.

The study showed that WVE-007 significantly reduced visceral fat, the dangerous fat surrounding internal organs, and increased muscle mass in adults with an average starting body mass index (BMI) of 32. After three months of treatment, patients receiving WVE-007 experienced a 9.4% reduction in visceral fat and a 4.5% decrease in total body fat compared to their baseline. The placebo group showed no statistically significant changes.

Wave Life Sciences reported that WVE-007 was generally safe and well-tolerated, with only mild treatment-related adverse events observed.

Buoyed by these promising results, Wave Life Sciences plans to initiate mid-stage clinical trials to further evaluate WVE-007’s potential. The company is exploring its use as a standalone obesity treatment, as an add-on therapy to existing GLP-1-based drugs like Ozempic and Wegovy, and as a maintenance option for patients discontinuing those GLP-1 therapies.

Despite today’s jump, Wave Life Sciences stock was down 39.4% year-to-date prior to the announcement, making today’s news a welcome boost for investors.

Read More